New lipid-lowering drug obicetrapib reduces LDL cholesterol and lipoprotein(a)
Two phase III studies presented at the European Atherosclerosis Congress (EAS) confirm the safety and efficacy of lipid lowering with the CETP inhibitor obicetrapib in patients with high cardiovascular risk.
Arzte zeitung
